Research Capital analyst André Uddin reiterated his “Speculative Buy” rating and C$12.00 target price for Eupraxia ...
Insilico announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules ...
Q3 2025 Earnings Call Transcript November 5, 2025 Charles River Laboratories International, Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Ladies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback